Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 15/20 | 0.34 |
| ▸ | CKS1B | P61024 | 1/20 | 0.32 |
| ▸ | SKP1 | P63208 | 1/20 | 0.32 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.32 |
| ▸ | RAF1 | P04049 | 3/20 | 0.32 |
| ▸ | BRAF | P15056 | 2/20 | 0.32 |
| ▸ | PTPRB | P23467 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17618872 | 0.89 | RAF1 (0.35) | RORCRAF1BRAF | |
| SCHEMBL17618871 | 0.86 | RHOA (0.35) | RORCRAF1BRAF | |
| SCHEMBL17624672 | 0.81 | RHOA (0.35) | RORCCKS1BSKP1SKP2 | |
| SCHEMBL19365701 | 0.80 | RHOA (0.35) | RORCCKS1BSKP1SKP2PTPRB | |
| SCHEMBL19365673 | 0.80 | RHOA (0.39) | — | |
| SCHEMBL16250015 | 0.78 | RHOA (0.38) | RAF1BRAF | |
| SCHEMBL19365867 | 0.78 | RHOA (0.37) | RORC | |
| SCHEMBL17624583 | 0.78 | RHOA (0.37) | RORC | |
| SCHEMBL17618874 | 0.77 | RAF1 (0.35) | RORCRAF1BRAF | |
| SCHEMBL19365383 | 0.76 | CA1 (0.37) | PTPRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | RORC 2889/4885CKS1B 698/4885SKP1 967/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | RORC 2889/4885CKS1B 698/4885SKP1 967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.